Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $2.8 million.

  • Voyager Therapeutics' Non Operating Income fell 4172.42% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year decrease of 2010.39%. This contributed to the annual value of $19.0 million for FY2024, which is 6163.43% up from last year.
  • Latest data reveals that Voyager Therapeutics reported Non Operating Income of $2.8 million as of Q3 2025, which was down 4172.42% from $3.3 million recorded in Q2 2025.
  • Voyager Therapeutics' 5-year Non Operating Income high stood at $4.9 million for Q2 2024, and its period low was -$1.6 million during Q2 2021.
  • Its 5-year average for Non Operating Income is $2.5 million, with a median of $3.2 million in 2022.
  • Per our database at Business Quant, Voyager Therapeutics' Non Operating Income crashed by 62766.67% in 2021 and then skyrocketed by 591290.32% in 2023.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Non Operating Income stood at $397000.0 in 2021, then soared by 140.05% to $953000.0 in 2022, then surged by 230.95% to $3.2 million in 2023, then soared by 39.38% to $4.4 million in 2024, then plummeted by 36.65% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $3.3 million for Q2 2025, and $3.7 million during Q1 2025.